Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Lusong Luo"'
Autor:
Xi Yuan, Zhiyu Tang, Rong Du, Zhan Yao, Shing‐Hu Cheung, Xinwen Zhang, Jing Wei, Yuan Zhao, Yunguang Du, Ye Liu, Xiaoxia Hu, Wenfeng Gong, Yong Liu, Yajuan Gao, Zhiyue Huang, Zongfu Cao, Min Wei, Changyou Zhou, Lai Wang, Neal Rosen, Paul D. Smith, Lusong Luo
Publikováno v:
Molecular Oncology, Vol 14, Iss 8, Pp 1833-1849 (2020)
The mutation of K‐RAS represents one of the most frequent genetic alterations in cancer. Targeting of downstream effectors of RAS, including of MEK and ERK, has limited clinical success in cancer patients with K‐RAS mutations. The reduced sensiti
Externí odkaz:
https://doaj.org/article/3c9d127250f544f0b8e196531da074da
Autor:
Yunhang Guo, Nan Hu, Ye Liu, Wei Zhang, Desheng Yu, Gongyin Shi, Bo Zhang, Longbo Yin, Min Wei, Xi Yuan, Lusong Luo, Fan Wang, Xiaomin Song, Lei Xin, Qiang Wei, Yong Li, Ying Guo, Shuaishuai Chen, Taichang Zhang, Shuo Zhang, Xing Zhou, Cuining Zhang, Dan Su, Junhua Liu, Zhenzhen Cheng, Jiye Zhang, Haimei Xing, Hanzi Sun, Xin Li, Yuan Zhao, Min He, Yue Wu, Yin Guo, Xuebing Sun, Alice Tian, Changyou Zhou, Steve Young, Xuesong Liu, Lai Wang, Zhiwei Wang
Publikováno v:
Journal of Medicinal Chemistry. 66:4025-4044
Autor:
Lusong Luo, Lai Wang, Changyou Zhou, Min Wei, David Sutton, Shuangxi Li, Lianhai Zhang, Jiafu Ji, Shaohui Wang, Shengjian Li, Rui Hao, Ye Liu, Yajuan Gao, Yong Liu, Wenfeng Gong, Xiaoxia Hu, Yunguang Du, Yi Zhang, Hao Peng, Yingcai Feng, Yuan Zhao, Jing Wei, Guoliang Zhang, Shing-Hu Cheung, Rong Du, Xi Yuan, Zhiyu Tang
Supplementary Tables S1-S6 and Supplementary Figures S1-S2. Table S1: Data collection and refinement statistics, related to Figure 1B; Table S2: Summary of cell line related information; Table S3: BGB-283 is a reversible B-RAF inhibitor; Table S4. Ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e1162ae1e5106b32e559ede087e8b9
https://doi.org/10.1158/1535-7163.22505985
https://doi.org/10.1158/1535-7163.22505985
Autor:
Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, Alastair J. King
Supplementary Figure 2 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b44fc16eeff8bc76ddb0a7cbaf43c3c
https://doi.org/10.1158/0008-5472.22366893
https://doi.org/10.1158/0008-5472.22366893
Autor:
Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, Alastair J. King
Supplementary Figure 3 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0381879a2c972a32b228b92d1ab7d021
https://doi.org/10.1158/0008-5472.22366890
https://doi.org/10.1158/0008-5472.22366890
Autor:
Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, Alastair J. King
Supplementary Figure 1 from Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a844d6f2ddb9f8350543123fa932bd
https://doi.org/10.1158/0008-5472.22366896.v1
https://doi.org/10.1158/0008-5472.22366896.v1
Autor:
Pearl S. Huang, David A. Tuveson, Michael M. Morrissey, Meenhard Herlyn, Keiran S.M. Smalley, Rooja G. Contractor, Jerry L. Adams, Ami S. Lakdawala, Lusong Luo, Michael D. Schaber, Cynthia M. Rominger, Earl W. May, Thomas J. Stout, David Chau, Jae Lee, Julie C. Lougheed, Florian Karreth, Lifu Wang, Erin Hugger, David M. Wilson, Andrew K. Takle, David W. Rusnak, Rakesh Kumar, Shu Yun Zhang, Hieu T. Do, Maureen L. Ho, Roberta S. Batorsky, Denis R. Patrick, Alastair J. King
Oncogenic BRAF alleles are both necessary and sufficient for cellular transformation, suggesting that chemical inhibition of the activated mutant protein kinase may reverse the tumor phenotype. Here, we report the characterization of SB-590885, a nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ae9912cc76ff8cd428267b7e6b1596
https://doi.org/10.1158/0008-5472.c.6495336.v1
https://doi.org/10.1158/0008-5472.c.6495336.v1
Autor:
Benjamin Solomon, Bo Gao, Vivek Subbiah, Michael Millward, Lee Rosen, Jayesh Desai, Eric I. Sbar, Neal Collins, Thuy Hoang, Xi Song, Wenlin Shao, Jaspreet Jaggi, Badreddin Edris, Paraneedharan Ramachandran, Lusong Luo, Michael Friedlander
Publikováno v:
Cancer Research. 83:CT033-CT033
Background: RAF dimer inhibition can suppress RAF-dependent MEK reactivation leading to sustained MAPK pathway inhibition. RAF dimer inhibitor lifirafenib (L) synergized with MEK inhibitor mirdametinib (M) in RAS-mutated cancer models. In this ongoin
Autor:
Alison M. Schram, Vivek Subbiah, Ryan Sullivan, Rasha Cosman, Jia Liu, Eric I. Sbar, Thuy Hoang, Jiarong Chen, Mark Johnson, Vincent Amoruccio, Todd Shearer, Adeela Kamal, Jocelyn Lewis, Wenlin Shao, Badreddin Edris, Lusong Luo, Jayesh Desai
Publikováno v:
Cancer Research. 83:CT031-CT031
Background: BGB-3245 is a RAF dimer inhibitor with preclinical activity in MAPK-altered tumor models harboring BRAF V600 mutations, atypical BRAF mutations/fusions, and RAS mutations. This study is investigating the safety, pharmacokinetics, and prel
Autor:
Zhen Qin, Ye Liu, Yong Liu, Dan Su, Dexu Xu, Yuan Zhao, Hao Peng, Lusong Luo, Bo Ren, Fan Wang, Changxin Huo, Min Wei, Yingcai Feng, Huibin Yan, Qiu Ming, Yin Guo, Kuang Xianzhao, Wenfeng Gong, Zhiwei Wang, Hong Xu, Xuebing Sun, Yajuan Gao, Xuesong Liu, Ruipeng Qi, Lai Wang, Beibei Jiang, Changyou Zhou, Yiyuan Wu, Fenglong Yu, Yutong Zhu, Hexiang Wang, Lei Lv, Xing Wang, Tristin Tang
Publikováno v:
Journal of Medicinal Chemistry. 63:15541-15563
Poly (ADP-ribose) polymerase (PARP) plays a significant role in DNA repair responses; therefore, this enzyme is targeted by PARP inhibitors in cancer therapy. Here we have developed a number of fused tetra- or pentacyclic dihydrodiazepinoindolone der